School of Medicine
Showing 1-48 of 48 Results
-
Yiyun Chen
Postdoctoral Scholar, Stanford Cancer Center
BioYiyun Chen, Ph.D. is a Postdoctoral Fellow at Professor Crystal Mackall’s group at Stanford Cancer Institute.
Dr. Chen studied biochemistry and structural biology in her undergraduate and master trainings at The Hong Kong University of Science and Technology, where she eventually obtained her Ph.D. degree in computational biology under the supervision of Professor Jiguang Wang. During her Ph.D. training, she has developed her skill sets in analyzing and integrating various types of patient-derived sequencing data, published three first-author and four co-author papers, and received two awards for top postgraduate students. Through interdisciplinary collaborations with cancer biologist and clinicians in US and Asia, her work has uncovered tumor-specific immune cell subtypes and novel noncoding RNAs and generated new insights into precision medicine in glioma, lymphoma and gastric cancer.
Applying her expertise in computational cancer biology and immunology, her current research is focused on identifying molecular mechanisms that contribute to the clinical outcomes of patients undergoing CAR-T immunotherapy. At Mackall Lab, she will contribute to tailoring computational pipelines for profiling the spatiotemporal dynamics of the tumor and immune microenvironment and translate new discoveries into cancer therapeutics. -
Muhammad Murtaza Hassan
Postdoctoral Scholar, Stanford Cancer Center
BioMurtaza is a chemical biologist that joined the Gray Lab in July 2021 as a postdoctoral researcher. He developed his love for medicinal chemistry and chemical biology at the undergraduate level at the University of Toronto Mississauga which then motivated him to pursue an MSc (York University, Supervisor: Prof. Edward Lee-Ruff, 2017) and PhD (University of Toronto Mississauga, Supervisor: Patrick T. Gunning, 2021) in the field. His PhD work involved the development of some of the most potent and selective HDAC8 inhibitors known-to-date. It incorporated inhibitors with L-shaped conformational constraints to compliment the L-shaped HDAC8 pocket. His current work at the Gray Lab revolves around the development of first-in-class covalent inhibitors for recently discovered epigenetic targets that have been shown to synergize with anticancer immunotherapy. Additionally, he is interested in developing small-molecule chemoproteomic tools that can potentially expand our ability to target otherwise undruggable proteins, by using protein-protein interactions for cross-labelling/drugging interacting proteins.
-
Anne Marijn Kramer
Postdoctoral Scholar, Stanford Cancer Center
BioDr. Anne Marijn Kramer, MD, PhD, is a postdoctoral research fellow in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Kramer received her medical degree (with honors) from Amsterdam University in 2013. She conducted her PhD studies at University College London, studying binding kinetics of Chimeric Antigen Receptor (CAR) T cells. Her research at Stanford University focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.
-
Lushun Wang
Postdoctoral Scholar, Stanford Cancer Center
BioLushun received his Ph.D. in organic chemistry from the School of Chemical Biology and Biotechnology at Peking University under the supervision of Professor Tao Ye. During his Ph.D. he focused on total syntheses of marine natural products. After post-doctoral training focusing on photocatalysis and fluorescent probes in Ting Wang’s group at SUNY Albany and Han Xiao’s group at Rice University, respectively, he joined Gray lab in 2022. Currently, he is interested in the development of novel therapeutics for cancer treatment.
-
An Ni Zhang
Postdoctoral Scholar, Stanford Cancer Center
BioAnni obtained her Ph.D. in Dr. James Johnson and Dr. Janel Kopp's labs at the University of British Columbia. Her Ph.D. work showed that hyperinsulinemia contributes to pancreatic cancer development. Her work also showed that insulin directly acted via the insulin receptors in pancreatic acinar cells to increase digestive enzyme production, thereby generating an inflammatory condition that accelerates neoplastic transformation. She is now working at Diehn lab to investigate the mechanisms of KEAP1 mutation-induced immunotherapy resistance in lung cancer.
